Chronic hepatitis C with repeatedly normal serum transaminases
Medecine/Sciences, ISSN: 0767-0974, Vol: 18, Issue: 3, Page: 357-361
2002
- 4Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures4
- Readers4
Article Description
An estimated 25% of patients with chronic hepatitis C virus (HCV) infection have persistently normal serum alanine aminotransferose (ALAT). These patients have only mild hepatitis and they may either not progress to cirrhosis at all or progress at a much slower rate than persons with elevated serum ALT levels. Given the limited response to IFN and IFN-ribavirin combination therapy, it was recommended that these patients should not be usually treated. Because of the great improved response rate observed with pegIFN plus ribavirine, these recommendations will probably be discussed again in patients with a high probability of sustained response.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036221928&origin=inward; http://dx.doi.org/10.1051/medsci/2002183357; http://www.medecinesciences.org/10.1051/medsci/2002183357; http://www.medecinesciences.org/10.1051/medsci/2002183357/pdf; https://dx.doi.org/10.1051/medsci/2002183357; https://www.medecinesciences.org/articles/medsci/full_html/2002/03/medsci2002183p357/medsci2002183p357.html
EDP Sciences
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know